Comment from Anita Tibau

Summary: Anita Vazquez Tibau, an individual petitioner, is requesting that the FDA include a notice of a formal OIG investigation in the administrative record. She argues that the FDA's reliance on the Casa Pia Children's Amalgam Trial data is procedurally deficient due to documented mismanagement, regulatory noncompliance, and data integrity issues.